Twist Bioscience (TWST) Set to Release Earnings on Thursday

Twist Bioscience (NASDAQ:TWST) is expected to issue its Q4 2026 results before the market opens on Thursday, November 12th. Analysts expect Twist Bioscience to announce earnings of ($0.3871) per share and revenue of $123.55 million for the quarter. Parties may visit the company’s upcoming Q4 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:00 AM ET.

Twist Bioscience Stock Performance

Shares of Twist Bioscience stock opened at $132.13 on Wednesday. The firm has a market cap of $8.29 billion, a PE ratio of -59.52 and a beta of 2.25. The firm’s 50-day simple moving average is $151.09 and its 200-day simple moving average is $91.97. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67. Twist Bioscience has a 1 year low of $23.30 and a 1 year high of $219.71.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Guggenheim lifted their price target on Twist Bioscience from $107.00 to $212.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. BWS Financial restated a “sell” rating and set a $45.00 price objective on shares of Twist Bioscience in a research note on Friday, September 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research note on Monday, September 21st. Leerink Partners increased their target price on Twist Bioscience from $160.00 to $190.00 and gave the stock an “outperform” rating in a report on Tuesday, September 29th. Finally, Canaccord Genuity Group lifted their target price on Twist Bioscience from $120.00 to $205.00 and gave the stock a “buy” rating in a research report on Monday, October 12th. Seven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Twist Bioscience presently has a consensus rating of “Hold” and an average price target of $153.00.

Insider Buying and Selling

In other Twist Bioscience news, CFO Adam Laponis sold 8,057 shares of the firm’s stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $188.88, for a total value of $1,521,806.16. Following the sale, the chief financial officer directly owned 100,576 shares in the company, valued at approximately $18,996,794.88. This trade represents a 7.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Emily Leproust sold 356,546 shares of the firm’s stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $157.99, for a total value of $56,330,702.54. Following the completion of the sale, the chief executive officer owned 620,589 shares in the company, valued at $98,046,856.11. The trade was a 36.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 495,279 shares of company stock worth $80,489,387. 3.08% of the stock is owned by company insiders.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.